Pfizer’s landmark Phase 3 TALAPRO-3 trial confirms that the Talzenna Xtandi rPFS mCSPC combination markedly exceeds its pre-specified efficacy target — advancing PARP inhibition earlier into the prostate cancer treatment course than ever before proven in a randomised study.
Eli Lilly and Company announced positive topline results from TRANSCEND-T2D-1, a landmark Phase 3 clinical trial evaluating retatrutide, an investigational triple hormone receptor agonist. The trial results demonstrate [Read More…]
ohnson & Johnson has announced FDA approval of ICOTYDE (icotrokinra), the first and only IL-23R targeted oral peptide designed for first-line systemic treatment of moderate-to-severe plaque psoriasis. This groundbreaking approval represents a paradigm shift in dermatology, offering patients unprecedented efficacy with complete skin clearance in over 70% of clinical trial participants.
Atirmociclib Phase 2Â data released mark a potentially defining moment in the treatment of hormone receptor-positive metastatic breast cancer. Pfizer’s investigational CDK4 inhibitor demonstrated a statistically [Read More…]
EBGLYSS (lebrikizumab) achieves groundbreaking Phase 3 results in children 6 months-18 years with moderate-to-severe atopic dermatitis. 63% achieved EASI-75 skin improvement. Learn about this selective IL-13 inhibitor breakthrough.
FDA warning letter reveals systemic failures in Novo Nordisk’s semaglutide safety reporting. Details on 15-day reporting violations, deaths, and suicides not reported to FDA. Regulatory analysis and consequences.
osentyx FDA approval marks first IL-17A inhibitor for pediatric patients 12+ with hidradenitis suppurativa. Discover how this breakthrough treatment transforms care for adolescents facing HS.
Johnson & Johnson announces 89% complete response rate with Erda-iDRS for intermediate-risk non-muscle-invasive bladder cancer. First-in-human trial shows durable 18-month responses with tolerable safety profile.
Groundbreaking clinical trial demonstrates that FreeStyle Libre continuous glucose monitoring technology significantly improves glucose management in people with Type 2 diabetes using basal insulin therapy, with patients achieving better HbA1c reduction and more time spent in healthy glucose ranges compared to traditional fingerstick monitoring.
While Roche’s persevERA trial didn’t meet its primary endpoint, the pharmaceutical company remains committed to advancing giredestrant as a new standard-of-care endocrine therapy. The FDA has accepted the company’s New Drug Application based on positive evERA data, signaling promise for this ER-positive breast cancer treatment.
